8-K: Corcept's ROSELLA Trial Meets Ovarian Cancer OS Endpoint

Corcept Therapeutics announced its pivotal Phase 3 ROSELLA trial for relacorilant in platinum-resistant ovarian cancer met its overall survival primary endpoint, showing a 35% reduction in death risk.

Summary

• Corcept Therapeutics' pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer met its overall survival (OS) primary endpoint.
• Patients treated with relacorilant plus nab-paclitaxel experienced a 35% reduction in the risk of death compared to nab-paclitaxel alone (hazard ratio: 0.65; p-value: 0.0004).
• Median OS for patients receiving relacorilant was 16.0 months, compared to 11.9 months for nab-paclitaxel alone, a difference of 4.1 months.
• The trial also previously met its primary endpoint of improved progression-free survival (PFS-BICR), showing a 30% reduction in the risk of disease progression (hazard ratio: 0.70; p-value: 0.008).
• Relacorilant in combination with nab-paclitaxel was well-tolerated, with comparable type, frequency, and severity of adverse events to the nab-paclitaxel monotherapy arm.
• The benefits were observed without the need for biomarker selection and without increased safety burden.
• Relacorilant's New Drug Application (NDA) is under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of July 11, 2026.
• A Marketing Authorization Application (MAA) for relacorilant for patients with platinum-resistant ovarian cancer is also under review by the European Medicines Agency (EMA).

Sentiment

Score: 9

Explanation: The announcement of meeting both primary endpoints (overall survival and progression-free survival) in a pivotal Phase 3 trial for a serious condition with limited treatment options, coupled with a favorable safety profile and regulatory applications under review, represents a highly positive development for the company and its future prospects.

Positives

• Met overall survival (OS) primary endpoint in pivotal Phase 3 ROSELLA trial.
• Demonstrated a 35% reduction in the risk of death (hazard ratio: 0.65; p-value: 0.0004).
• Increased median overall survival by 4.1 months (16.0 months vs. 11.9 months).
• Previously met progression-free survival (PFS) primary endpoint, showing a 30% reduction in disease progression risk (hazard ratio: 0.70; p-value: 0.008).
• Well-tolerated safety profile, comparable to nab-paclitaxel monotherapy, without increasing safety burden.
• Effective without the need for biomarker selection.
• Oral administration offers convenience for patients.
• NDA and MAA are under review by FDA and EMA, respectively, indicating progress towards market approval.

Risks

• Actual results might differ materially from forward-looking statements due to various risks and uncertainties inherent in drug development and regulatory processes.

Future Outlook

Relacorilant combined with nab-paclitaxel is positioned to become a new standard-of-care treatment for patients with platinum-resistant ovarian cancer. Corcept is evaluating relacorilant for earlier stages of ovarian cancer and other tumors expressing the glucocorticoid receptor, such as endometrial and cervical cancer. The company is currently studying relacorilant in platinum-sensitive ovarian, endometrial, cervical, pancreatic, and prostate cancers, and aims to bring this new treatment to patients as soon as possible.

Management Comments

• "The addition of relacorilant to nab-paclitaxel, a trusted and effective chemotherapy, is positioned to become a new standard-of-care treatment for patients with platinum-resistant ovarian cancer, due to its overall survival benefit, well tolerated side effect profile and oral administration. Importantly, the Phase 3 trial results are not limited to patients with any particular biomarker requirement." Alexander B. Olawaiye, M.D., Director of gynecological cancer research at Magee-Womens Hospital of the University of Pittsburgh and Principal Investigator in the ROSELLA trial.
• "ROSELLAs findings compel us to evaluate relacorilant as a treatment for earlier stages of ovarian cancer and for other tumors that express the glucocorticoid receptor, such as endometrial and cervical cancer." Alexander B. Olawaiye, M.D.
• "These data clearly demonstrate the potential of relacorilant plus nab-paclitaxel to extend overall and progression-free survival in patients with advanced, recurrent ovarian cancer. These tumors eventually become resistant to chemotherapy and providing oncologists with relacorilant plus nab-paclitaxel could greatly benefit patients." Domenica Lorusso, M.D., Ph.D., Director of the Gynaecological Oncology Unit at Humanitas Hospital San Pio X in Milan, and Full Professor of Obstetrics and Gynaecology at Humanitas University, Rozzano and an investigator in the ROSELLA trial.
• "We are working with regulatory authorities in the U.S. and Europe to bring this much-needed new treatment to patients as soon as possible." Bill Guyer, PharmD, Corcept's Chief Development Officer.

Industry Context

Ovarian cancer is the fifth most common cause of cancer death in women, with platinum-resistant disease having few treatment options. Relacorilant's success in improving overall and progression-free survival in this challenging patient population addresses a critical unmet medical need, potentially establishing a new standard of care. Corcept's focus on cortisol modulation, which plays a role in tumor growth and chemotherapy resistance, positions relacorilant for broader applicability in oncology beyond ovarian cancer.

Comparison to Industry Standards

• Relacorilant plus nab-paclitaxel is positioned to become a new standard-of-care treatment for patients with platinum-resistant ovarian cancer, implying a significant improvement over existing limited treatment options.
• The combination was well-tolerated, with a safety profile comparable to nab-paclitaxel monotherapy, a "trusted and effective chemotherapy," suggesting it adds substantial therapeutic benefit without increasing the burden of side effects typically associated with chemotherapy.

Stakeholder Impact

• Shareholders: Highly positive news, potentially leading to increased stock value due to successful trial results and clearer path to market for a significant new treatment.
• Patients with platinum-resistant ovarian cancer: Significant benefit from a new, effective, and well-tolerated treatment option that extends overall and progression-free survival in a disease with limited therapeutic choices.
• Oncologists: Provided with a new, effective treatment option for a challenging patient population, potentially establishing a new standard of care.
• Employees: Positive impact on morale and job security due to company success and progress in drug development.

Next Steps

• Presentation of complete ROSELLA trial results at an upcoming medical conference.
• Continued review of Relacorilant's New Drug Application (NDA) by the U.S. FDA (PDUFA target date July 11, 2026).
• Continued review of Relacorilant's Marketing Authorization Application (MAA) by the European Medicines Agency (EMA).
• Evaluation of relacorilant as a treatment for earlier stages of ovarian cancer.
• Evaluation of relacorilant for other tumors expressing the glucocorticoid receptor (e.g., endometrial, cervical cancer).
• Ongoing studies of relacorilant in platinum-sensitive ovarian, endometrial, cervical, pancreatic, and prostate cancers.

Key Dates

Recommendation

The successful completion of a pivotal Phase 3 trial, meeting both overall survival and progression-free survival endpoints with a favorable safety profile, for a drug addressing a high unmet medical need (platinum-resistant ovarian cancer), is a significant de-risking event. With regulatory applications already under review in the US and Europe, the path to market appears clearer, indicating strong potential for future revenue growth and market share. This positive clinical outcome, combined with the potential for broader application in other cancers, makes Corcept Therapeutics a compelling investment.

Keywords

Corcept Therapeutics, CORT, relacorilant, ovarian cancer, platinum-resistant ovarian cancer, ROSELLA trial, Phase 3, overall survival, progression-free survival, nab-paclitaxel, FDA, EMA, PDUFA, oncology, cortisol modulation, glucocorticoid receptor antagonist